MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis

Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An alt...

Full description

Saved in:
Bibliographic Details
Published inMedical oncology (Northwood, London, England) Vol. 28; no. 4; pp. 1549 - 1554
Main Authors Penna, G., Allegra, A., Alonci, A., Aguennouz, M., Garufi, A., Cannavò, A., Gerace, D., Alibrandi, A., Musolino, C.
Format Journal Article
LanguageEnglish
Published Boston Springer US 01.12.2011
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1357-0560
1559-131X
1559-131X
DOI10.1007/s12032-010-9561-9

Cover

Abstract Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed ( P  = 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes ( r  = 0.209, P  = 0.01). Moreover, the same genotype was correlated with lymphocyte number ( r  = 0.269, P  = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels ( r  = 0.247, P  = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.
AbstractList Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P=0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r=0.209, P=0.01). Moreover, the same genotype was correlated with lymphocyte number (r=0.269, P=0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r=0.247, P=0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P=0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r=0.209, P=0.01). Moreover, the same genotype was correlated with lymphocyte number (r=0.269, P=0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r=0.247, P=0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed ( P  = 0.009). When comparing the prognostic patients’ characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes ( r  = 0.209, P  = 0.01). Moreover, the same genotype was correlated with lymphocyte number ( r  = 0.269, P  = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels ( r  = 0.247, P  = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.
Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous prognosis. Novel biological markers such as IgVH mutation, CD38, and ZAP-70 expression have shown to offer important prognostic information. An altered expression of the multidrug resistance 1 may represent an additional prognostic marker. Aim of our study was to evaluate two MDR-1 gene polymorphisms: G2677T polymorphism in exon 21 and C3435T polymorphism in exon 26, to evidence if polymorphisms influence the risk of development of B-CLL and whether genomic polymorphisms provide prognostic information on the clinical progression of the disease. A total of 125 patients with B-CLL and 125 healthy subjects were enrolled in this study. The mutant homozygous 2677 TT genotype was found to be associated with the occurrence of B-CLL and higher T allele frequency in patients with B-CLL when compared with controls was observed (P = 0.009). When comparing the prognostic patients' characteristics, patients with 2677 GT genotype were statistically linked to the unmutated IgVH genes (r = 0.209, P = 0.01). Moreover, the same genotype was correlated with lymphocyte number (r = 0.269, P = 0.02). Finally for the 2677GT polymorphism, the heterozygous status was associated with higher hemoglobin levels (r = 0.247, P = 0.005). As far the C3435T MDR1 polymorphism, we were not able to identify any significant correlation with IgVH gene status or other variables. In conclusion, MDR1 gene polymorphism could be a factor predisposing to LLC. Moreover, our findings support the possibility of considering these genomic polymorphisms as prognostic markers in patients with B-CLL.[PUBLICATION ABSTRACT]
Author Penna, G.
Musolino, C.
Alonci, A.
Garufi, A.
Cannavò, A.
Gerace, D.
Allegra, A.
Alibrandi, A.
Aguennouz, M.
Author_xml – sequence: 1
  givenname: G.
  surname: Penna
  fullname: Penna, G.
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
– sequence: 2
  givenname: A.
  surname: Allegra
  fullname: Allegra, A.
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
– sequence: 3
  givenname: A.
  surname: Alonci
  fullname: Alonci, A.
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
– sequence: 4
  givenname: M.
  surname: Aguennouz
  fullname: Aguennouz, M.
  organization: Department of Neuroscience, Policlinico G. Martino, University of Messina
– sequence: 5
  givenname: A.
  surname: Garufi
  fullname: Garufi, A.
  organization: Department of Neuroscience, Policlinico G. Martino, University of Messina
– sequence: 6
  givenname: A.
  surname: Cannavò
  fullname: Cannavò, A.
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
– sequence: 7
  givenname: D.
  surname: Gerace
  fullname: Gerace, D.
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
– sequence: 8
  givenname: A.
  surname: Alibrandi
  fullname: Alibrandi, A.
  organization: Department of Statistics, University of Messina
– sequence: 9
  givenname: C.
  surname: Musolino
  fullname: Musolino, C.
  email: cmusolino@unime.it
  organization: Division of Hematology, Policlinico G. Martino, University of Messina
BackLink https://www.ncbi.nlm.nih.gov/pubmed/20496015$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtv1DAUhS1URB_wA9igiA1lYfD1c9wdDFCQipDQILGLHMfpuCR2sJ3F_Hs8TAGpEl35Lr5z7vU5p-goxOAQegrkFRCiXmeghFFMgGAtJGD9AJ2AEBoDg-9HdWZCYSIkOUanOd8QQkFQ_QgdU8K1JCBOUPn87iuGZo7jbopp3vo85eb8kkqlNo0JfbNmnInNy8aH5i222xSDt02F5220u7Kf3fLDTd5cVLzx02xsaWJo8pKtm4vv_OjL7rfVnOJ1iNnnx-jhYMbsnty-Z-jbh_eb9Ud89eXy0_rNFbacsIIdFbpbwcoKySUFbfre9EyajivRDaApd7wbiF2tagr1YEGUpAPpHLBB9qDYGXpx8K2bfy4ul3by9apxNMHFJbe6ZqM0I6tKnt9LApe82lPFK_r8DnoTlxTqP6ofFyC5FhV6dgst3eT6dk5-MmnX_gm-AnAAbIo5Jzf8RYC0-3LbQ7ltLbfdl9vqqlF3NNYXU3wMJRk_3qukB2WuW8K1S_9u_r_oF3k_tKU
CODEN MONCEZ
CitedBy_id crossref_primary_10_1007_s00580_013_1859_5
crossref_primary_10_3390_antiox13040475
crossref_primary_10_1007_s13277_014_2914_9
crossref_primary_10_1016_j_bios_2012_07_018
crossref_primary_10_1007_s11033_012_1554_7
crossref_primary_10_3390_molecules23010119
crossref_primary_10_1007_s00580_012_1581_8
crossref_primary_10_1007_s12254_018_0446_5
crossref_primary_10_1007_s13277_013_1291_0
crossref_primary_10_3109_10428194_2011_641179
crossref_primary_10_1186_1475_2867_13_46
crossref_primary_10_3109_10428194_2013_800197
crossref_primary_10_1111_ecc_12067
Cites_doi 10.1007/978-1-4615-4811-9_9
10.1016/j.ejphar.2005.10.068
10.1016/0145-2126(94)90085-X
10.1159/000220331
10.1080/10245330310001638974
10.1016/j.clpt.2003.09.012
10.1182/blood-2005-08-3272
10.1016/S0198-8859(02)00426-3
10.1002/ijc.21666
10.1089/dna.2008.0826
10.1182/blood-2008-03-147744
10.1080/10428190701457931
10.1023/A:1013177710941
10.1067/mcp.2001.117412
10.1016/j.leukres.2008.06.008
10.1097/00008571-200106000-00003
10.1016/S0169-409X(02)00064-9
10.1016/j.clpt.2006.07.005
10.1073/pnas.050585397
10.1159/000086579
10.1532/IJH97.E0418
10.1023/A:1026331326648
10.1111/j.1365-2141.2004.05319.x
10.1097/FPC.0b013e3282f82297
10.1080/10428190600881421
10.1007/BF01836067
10.1111/j.1600-0609.2004.00228.x
10.1016/S0959-8049(98)00230-5
10.1111/j.1365-2141.2007.06605.x
10.1016/j.arcmed.2007.02.005
10.1016/j.leukres.2007.04.009
10.1182/blood.V94.6.1848
10.1080/10428190701534473
10.1182/blood.V93.5.1496
10.1007/s12032-010-9456-9
ContentType Journal Article
Copyright Springer Science+Business Media, LLC 2010
Springer Science+Business Media, LLC 2011
Copyright_xml – notice: Springer Science+Business Media, LLC 2010
– notice: Springer Science+Business Media, LLC 2011
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
BENPR
CCPQU
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7T5
H94
7X8
DOI 10.1007/s12032-010-9561-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central
ProQuest One Community College
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
Immunology Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
ProQuest Health & Medical Research Collection
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
AIDS and Cancer Research Abstracts
Immunology Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
AIDS and Cancer Research Abstracts
MEDLINE

ProQuest One Academic Middle East (New)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1559-131X
EndPage 1554
ExternalDocumentID 2514239541
20496015
10_1007_s12032_010_9561_9
Genre Journal Article
Feature
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.GJ
.VR
06C
06D
0R~
0VY
2.D
203
28-
29M
29~
2J2
2JN
2JY
2KG
2KM
2LR
2VQ
2~H
30V
3V.
4.4
406
408
40E
53G
5GY
5RE
5VS
6NX
7X7
88E
8AO
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABDZT
ABECU
ABFTV
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABUWG
ABWNU
ABXPI
ACAOD
ACCUX
ACDTI
ACGFS
ACHSB
ACHVE
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADINQ
ADJJI
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADZKW
AEBTG
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFKRA
AFLOW
AFQWF
AFWTZ
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMXSW
AMYLF
AMYQR
AOCGG
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBWZM
BDATZ
BENPR
BGNMA
BPHCQ
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
EIOEI
EJD
EMOBN
ESBYG
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GRRUI
H13
HF~
HG6
HMCUK
HMJXF
HRMNR
HVGLF
HZ~
IJ-
IKXTQ
IMOTQ
IWAJR
IXD
I~X
I~Z
J-C
J0Z
JBSCW
JZLTJ
KOV
LLZTM
M1P
M4Y
MA-
N2Q
N9A
NDZJH
NF0
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OVD
P19
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
PZZ
Q2X
QOK
QOR
QOS
R89
R9I
RHV
RIG
RNI
ROL
RPX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TT1
TUC
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W48
WK8
YLTOR
Z7U
Z82
Z87
Z8O
Z8V
Z91
ZMTXR
ZOVNA
ZXP
~A9
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ABRTQ
ACSTC
ADHKG
AEZWR
AFDZB
AFHIU
AFOHR
AGQPQ
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
7T5
H94
7X8
ID FETCH-LOGICAL-c403t-e259b818c5646219addad36ab475bf1924e4bf0c8803267750762f0be13f6d173
IEDL.DBID 7X7
ISSN 1357-0560
1559-131X
IngestDate Fri Sep 05 09:41:24 EDT 2025
Fri Sep 05 14:21:29 EDT 2025
Sat Aug 23 14:07:41 EDT 2025
Mon Jul 21 05:52:50 EDT 2025
Wed Oct 01 02:31:07 EDT 2025
Thu Apr 24 22:52:56 EDT 2025
Fri Feb 21 02:38:20 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords B-chronic lymphocytic leukemia
MDR1
Gene polymorphism
Prognostic marker
Language English
License http://www.springer.com/tdm
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c403t-e259b818c5646219addad36ab475bf1924e4bf0c8803267750762f0be13f6d173
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-2
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
PMID 20496015
PQID 904516495
PQPubID 30753
PageCount 6
ParticipantIDs proquest_miscellaneous_905679308
proquest_miscellaneous_1464507274
proquest_journals_904516495
pubmed_primary_20496015
crossref_primary_10_1007_s12032_010_9561_9
crossref_citationtrail_10_1007_s12032_010_9561_9
springer_journals_10_1007_s12032_010_9561_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20111200
2011-12-00
2011-Dec
20111201
PublicationDateYYYYMMDD 2011-12-01
PublicationDate_xml – month: 12
  year: 2011
  text: 20111200
PublicationDecade 2010
PublicationPlace Boston
PublicationPlace_xml – name: Boston
– name: United States
– name: Middlesex
PublicationTitle Medical oncology (Northwood, London, England)
PublicationTitleAbbrev Med Oncol
PublicationTitleAlternate Med Oncol
PublicationYear 2011
Publisher Springer US
Springer Nature B.V
Publisher_xml – name: Springer US
– name: Springer Nature B.V
References Van der Holt (CR14) 2006; 80
Kim (CR11) 2005; 114
Kim, Park, Sohn, Lee, Lee (CR17) 2006; 91
Dulucq (CR18) 2008; 112
Hitzl (CR9) 2001; 11
Rochlitz (CR26) 1992; 65
Potocnik, Ravnik-Glavac, Glavac (CR32) 2002; 7
Pawlik, Baskiewicz-Masiuk, Machalinski, Kurzawski, Gawronska-Szklarz (CR35) 2005; 528
Jamroziak (CR25) 2009; 33
CR36
Krajinovic, Labuda, Richier, Karimi, Sinnett (CR31) 1999; 93
Jamroziak (CR29) 2004; 72
Rund, Azar, Shperling (CR28) 1999; 457
Hoffmeyer (CR8) 2000; 97
Hattori (CR30) 2007; 31
Tatari (CR23) 2009; 28
Golapud, Gupta (CR33) 2001; 21
Guillaume (CR27) 2007; 48
Jamroziak, Robak (CR4) 2004; 9
Buda (CR15) 2007; 137
Maggini (CR16) 2008; 18
Hamblin, Davis, Gardiner, Oscier, Stevenson (CR20) 1999; 94
Iyer, Raain (CR2) 1998; 34
Monzo (CR12) 2006; 107
Turgut, Yaren, Kursunluoglu, Turgut (CR22) 2007; 38
Mattews (CR34) 2006; 47
Tsopra, Ziros, Lagadinou, Symeonidis, Kouraklis-Symeonidis, Thanopoulou, Angelopoulou, Vassilakopoulos, Pangalis, Zoumbos (CR37) 2009; 121
Marzolini, Paulus, Buclin, Kim (CR5) 2004; 75
CR21
Kim (CR6) 2001; 70
Fromm (CR3) 2002; 54
Stanulla (CR13) 2005; 81
Wulf (CR1) 1994; 18
Goreva, Grishanova, Mukhin, Domnikova, Lyakhovich (CR24) 2003; 136
Zheng (CR19) 2002; 63
Kim (CR7) 2005; 118
Schaich, Sourcek, Thiede, Ehninger, Ilmer (CR10) 2005; 128
K Jamroziak (9561_CR4) 2004; 9
DH Kim (9561_CR11) 2005; 114
K Jamroziak (9561_CR25) 2009; 33
M Krajinovic (9561_CR31) 1999; 93
C Mattews (9561_CR34) 2006; 47
S Turgut (9561_CR22) 2007; 38
RB Kim (9561_CR6) 2001; 70
RB Kim (9561_CR7) 2005; 118
M Hitzl (9561_CR9) 2001; 11
H Zheng (9561_CR19) 2002; 63
N Guillaume (9561_CR27) 2007; 48
S Hoffmeyer (9561_CR8) 2000; 97
A Pawlik (9561_CR35) 2005; 528
C Marzolini (9561_CR5) 2004; 75
M Schaich (9561_CR10) 2005; 128
S Golapud (9561_CR33) 2001; 21
G Buda (9561_CR15) 2007; 137
OB Goreva (9561_CR24) 2003; 136
9561_CR36
CF Rochlitz (9561_CR26) 1992; 65
B Van der Holt (9561_CR14) 2006; 80
MF Fromm (9561_CR3) 2002; 54
M Monzo (9561_CR12) 2006; 107
G Wulf (9561_CR1) 1994; 18
M Stanulla (9561_CR13) 2005; 81
OA Tsopra (9561_CR37) 2009; 121
K Jamroziak (9561_CR29) 2004; 72
D Rund (9561_CR28) 1999; 457
TJ Hamblin (9561_CR20) 1999; 94
9561_CR21
U Potocnik (9561_CR32) 2002; 7
S Dulucq (9561_CR18) 2008; 112
L Iyer (9561_CR2) 1998; 34
DH Kim (9561_CR17) 2006; 91
V Maggini (9561_CR16) 2008; 18
H Hattori (9561_CR30) 2007; 31
F Tatari (9561_CR23) 2009; 28
1360821 - Ann Hematol. 1992 Dec;65(6):241-6
16103629 - Acta Haematol. 2005;114(2):78-83
17112800 - Clin Pharmacol Ther. 2006 Nov;80(5):427-39
15203864 - Hematology. 2004 Apr;9(2):91-105
15059065 - Eur J Haematol. 2004 May;72(5):314-21
12406646 - Adv Drug Deliv Rev. 2002 Nov 18;54(10):1295-310
18408561 - Pharmacogenet Genomics. 2008 May;18(5):383-9
17488488 - Br J Haematol. 2007 Jun;137(5):454-6
16769591 - Haematologica. 2006 Jun;91(6):848-51
16331627 - Int J Cancer. 2006 May 1;118(9):2195-201
17568669 - Leuk Res. 2007 Dec;31(12):1633-40
14631505 - Bull Exp Biol Med. 2003 Aug;136(2):183-5
10500782 - Adv Exp Med Biol. 1999;457:71-5
11434506 - Pharmacogenetics. 2001 Jun;11(4):293-8
17107902 - Leuk Lymphoma. 2006 Nov;47(11):2308-13
19388849 - DNA Cell Biol. 2009 May;28(5):259-63
20204543 - Med Oncol. 2011 Mar;28(1):265-9
19468203 - Acta Haematol. 2009;121(4):187-95
17701587 - Leuk Lymphoma. 2007 Aug;48(8):1556-60
14749689 - Clin Pharmacol Ther. 2004 Jan;75(1):13-33
17560460 - Arch Med Res. 2007 Jul;38(5):539-44
11503014 - Clin Pharmacol Ther. 2001 Aug;70(2):189-99
10716719 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
18524988 - Blood. 2008 Sep 1;112(5):2024-7
11811787 - J Clin Immunol. 2001 Nov;21(6):420-30
7912754 - Leuk Res. 1994 Jul;18(7):475-84
18639335 - Leuk Res. 2009 Feb;33(2):332-5
10477713 - Blood. 1999 Sep 15;94(6):1848-54
12175731 - Hum Immunol. 2002 Sep;63(9):765-70
11980438 - Cell Mol Biol Lett. 2002;7(1):92-5
10029576 - Blood. 1999 Mar 1;93(5):1496-501
15717687 - Int J Hematol. 2005 Jan;81(1):39-44
15667534 - Br J Haematol. 2005 Feb;128(3):324-32
9893619 - Eur J Cancer. 1998 Sep;34(10):1493-9
16321374 - Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36
16507781 - Blood. 2006 Jun 15;107(12):4871-9
References_xml – volume: 457
  start-page: 71
  year: 1999
  end-page: 75
  ident: CR28
  article-title: A mutation in the promoter of the multidrug resistance gene (MDR1) in human hematological malignancies may contribute to the pathogenesis of resistant disease
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-4811-9_9
– volume: 528
  start-page: 27
  year: 2005
  end-page: 36
  ident: CR35
  article-title: Involvement of C3435T and G 2677T multidrug resistance gene polymorphisms in release of cytokines from peripheral blood mononuclear cells treated with methotrexate and dexamethasone
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2005.10.068
– volume: 18
  start-page: 475
  year: 1994
  end-page: 484
  ident: CR1
  article-title: Multidrug resistance phenotype in patients with chronic lymphocytic leukemia as detected by immunofluorescence (FACS) and northen blot analysis
  publication-title: Leuk Res
  doi: 10.1016/0145-2126(94)90085-X
– volume: 91
  start-page: 848
  year: 2006
  end-page: 851
  ident: CR17
  article-title: The association between multidrug resistance-1 gene polymorphisms and outcomes of allogenic HLA-identical stem cell transplantation
  publication-title: Haematologica
– volume: 121
  start-page: 187
  year: 2009
  end-page: 195
  ident: CR37
  article-title: Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factor-alpha
  publication-title: Acta Haematol
  doi: 10.1159/000220331
– volume: 9
  start-page: 91
  year: 2004
  end-page: 105
  ident: CR4
  article-title: Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies
  publication-title: Hematology
  doi: 10.1080/10245330310001638974
– volume: 93
  start-page: 496
  year: 1999
  end-page: 1501
  ident: CR31
  article-title: Susceptibility to childhood lymphoblastic leukemia: influence of CYP1a1, CYP2D6, GSTM1 and GSTT1 genetic polymorphism
  publication-title: Blood
– volume: 75
  start-page: 13
  year: 2004
  end-page: 33
  ident: CR5
  article-title: Polimorphorsms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.09.012
– volume: 107
  start-page: 4871
  year: 2006
  end-page: 4879
  ident: CR12
  article-title: Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia
  publication-title: Blood
  doi: 10.1182/blood-2005-08-3272
– volume: 63
  start-page: 765
  year: 2002
  end-page: 770
  ident: CR19
  article-title: The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in paediatric heart transplant patients
  publication-title: Him Immunol
  doi: 10.1016/S0198-8859(02)00426-3
– volume: 118
  start-page: 2195
  year: 2005
  end-page: 2201
  ident: CR7
  article-title: Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in the novo acute myeloid leukemia
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21666
– volume: 28
  start-page: 259
  year: 2009
  end-page: 263
  ident: CR23
  article-title: Association of C3435T single-nucleotide polymorphism of MDR1 gene with breast cancer in an Iranian population
  publication-title: DNA Cell Biol
  doi: 10.1089/dna.2008.0826
– volume: 112
  start-page: 2024
  year: 2008
  end-page: 2027
  ident: CR18
  article-title: Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia
  publication-title: Blood
  doi: 10.1182/blood-2008-03-147744
– volume: 48
  start-page: 1468
  year: 2007
  end-page: 1469
  ident: CR27
  article-title: Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190701457931
– volume: 21
  start-page: 420
  year: 2001
  end-page: 430
  ident: CR33
  article-title: Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival
  publication-title: J Clin Immunol
  doi: 10.1023/A:1013177710941
– volume: 70
  start-page: 189
  year: 2001
  end-page: 199
  ident: CR6
  article-title: Identification of functionally variant MDR1 alleles among European Americans and African Americans
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2001.117412
– volume: 94
  start-page: 1848
  year: 1999
  end-page: 1854
  ident: CR20
  article-title: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia
  publication-title: Blood
– volume: 33
  start-page: 332
  year: 2009
  end-page: 335
  ident: CR25
  article-title: Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2008.06.008
– ident: CR21
– volume: 11
  start-page: 293
  year: 2001
  end-page: 298
  ident: CR9
  article-title: The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200106000-00003
– volume: 7
  start-page: 92
  year: 2002
  end-page: 95
  ident: CR32
  article-title: Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability
  publication-title: Cell Mol Biol Lett
– volume: 54
  start-page: 1295
  year: 2002
  end-page: 1310
  ident: CR3
  article-title: The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/S0169-409X(02)00064-9
– volume: 80
  start-page: 427
  year: 2006
  end-page: 439
  ident: CR14
  article-title: ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.07.005
– volume: 97
  start-page: 3473
  year: 2000
  end-page: 3478
  ident: CR8
  article-title: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.050585397
– volume: 114
  start-page: 78
  year: 2005
  end-page: 83
  ident: CR11
  article-title: Multidrug resistance as a potential prognostic indicator in acute myeoid leukemia with normal karyotypes
  publication-title: Acta Haematol
  doi: 10.1159/000086579
– volume: 81
  start-page: 39
  year: 2005
  end-page: 44
  ident: CR13
  article-title: GSTP1 and MDR1 genotypes and central nervous system relapse in childhood acute lymphoblastic leukemia
  publication-title: Int J Hematol
  doi: 10.1532/IJH97.E0418
– volume: 136
  start-page: 183
  year: 2003
  end-page: 185
  ident: CR24
  article-title: Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms
  publication-title: Bull Exp Biol Med
  doi: 10.1023/A:1026331326648
– volume: 128
  start-page: 324
  year: 2005
  end-page: 332
  ident: CR10
  article-title: MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2004.05319.x
– volume: 18
  start-page: 383
  year: 2008
  end-page: 389
  ident: CR16
  article-title: MDR1 diplotypes as prognostic markers in multiple myeloma
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3282f82297
– volume: 47
  start-page: 2308
  year: 2006
  end-page: 2313
  ident: CR34
  article-title: MDR-1, but not MDR-3 gene expression, is associated with unmutated IgVh genes and poor prognosis chromosomal aberrations in chronic lymphocytic leukemia
  publication-title: Leuk Lymph
  doi: 10.1080/10428190600881421
– ident: CR36
– volume: 65
  start-page: 241
  year: 1992
  end-page: 246
  ident: CR26
  article-title: PCR-determined expression of the MDR1 gene in chronic lymphocytic leukemia
  publication-title: Ann Hematol
  doi: 10.1007/BF01836067
– volume: 72
  start-page: 314
  year: 2004
  end-page: 321
  ident: CR29
  article-title: Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibly and clinical outcome of childhood acute lymphoblastic leukemia
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2004.00228.x
– volume: 34
  start-page: 1493
  year: 1998
  end-page: 1499
  ident: CR2
  article-title: Pharmacogenetics and cancer chemotherapy
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(98)00230-5
– volume: 137
  start-page: 454
  year: 2007
  end-page: 456
  ident: CR15
  article-title: MDR1 polymorphism influences the outcome of multiple myeloma patients
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2007.06605.x
– volume: 38
  start-page: 539
  year: 2007
  end-page: 544
  ident: CR22
  article-title: MDR1 C3435T polymorphism in patients with breast cancer
  publication-title: Arch Med Res
  doi: 10.1016/j.arcmed.2007.02.005
– volume: 31
  start-page: 1633
  year: 2007
  end-page: 1640
  ident: CR30
  article-title: Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukemia
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2007.04.009
– volume: 114
  start-page: 78
  year: 2005
  ident: 9561_CR11
  publication-title: Acta Haematol
  doi: 10.1159/000086579
– volume: 137
  start-page: 454
  year: 2007
  ident: 9561_CR15
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2007.06605.x
– volume: 33
  start-page: 332
  year: 2009
  ident: 9561_CR25
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2008.06.008
– volume: 7
  start-page: 92
  year: 2002
  ident: 9561_CR32
  publication-title: Cell Mol Biol Lett
– volume: 121
  start-page: 187
  year: 2009
  ident: 9561_CR37
  publication-title: Acta Haematol
  doi: 10.1159/000220331
– volume: 107
  start-page: 4871
  year: 2006
  ident: 9561_CR12
  publication-title: Blood
  doi: 10.1182/blood-2005-08-3272
– volume: 63
  start-page: 765
  year: 2002
  ident: 9561_CR19
  publication-title: Him Immunol
  doi: 10.1016/S0198-8859(02)00426-3
– volume: 94
  start-page: 1848
  year: 1999
  ident: 9561_CR20
  publication-title: Blood
  doi: 10.1182/blood.V94.6.1848
– volume: 118
  start-page: 2195
  year: 2005
  ident: 9561_CR7
  publication-title: Int J Cancer
  doi: 10.1002/ijc.21666
– volume: 18
  start-page: 383
  year: 2008
  ident: 9561_CR16
  publication-title: Pharmacogenet Genomics
  doi: 10.1097/FPC.0b013e3282f82297
– volume: 136
  start-page: 183
  year: 2003
  ident: 9561_CR24
  publication-title: Bull Exp Biol Med
  doi: 10.1023/A:1026331326648
– volume: 112
  start-page: 2024
  year: 2008
  ident: 9561_CR18
  publication-title: Blood
  doi: 10.1182/blood-2008-03-147744
– volume: 21
  start-page: 420
  year: 2001
  ident: 9561_CR33
  publication-title: J Clin Immunol
  doi: 10.1023/A:1013177710941
– volume: 70
  start-page: 189
  year: 2001
  ident: 9561_CR6
  publication-title: Clin Pharmacol Ther
  doi: 10.1067/mcp.2001.117412
– volume: 457
  start-page: 71
  year: 1999
  ident: 9561_CR28
  publication-title: Adv Exp Med Biol
  doi: 10.1007/978-1-4615-4811-9_9
– ident: 9561_CR36
– volume: 91
  start-page: 848
  year: 2006
  ident: 9561_CR17
  publication-title: Haematologica
– volume: 65
  start-page: 241
  year: 1992
  ident: 9561_CR26
  publication-title: Ann Hematol
  doi: 10.1007/BF01836067
– volume: 128
  start-page: 324
  year: 2005
  ident: 9561_CR10
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2004.05319.x
– volume: 72
  start-page: 314
  year: 2004
  ident: 9561_CR29
  publication-title: Eur J Haematol
  doi: 10.1111/j.1600-0609.2004.00228.x
– volume: 18
  start-page: 475
  year: 1994
  ident: 9561_CR1
  publication-title: Leuk Res
  doi: 10.1016/0145-2126(94)90085-X
– volume: 75
  start-page: 13
  year: 2004
  ident: 9561_CR5
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2003.09.012
– volume: 47
  start-page: 2308
  year: 2006
  ident: 9561_CR34
  publication-title: Leuk Lymph
  doi: 10.1080/10428190600881421
– volume: 34
  start-page: 1493
  year: 1998
  ident: 9561_CR2
  publication-title: Eur J Cancer
  doi: 10.1016/S0959-8049(98)00230-5
– volume: 9
  start-page: 91
  year: 2004
  ident: 9561_CR4
  publication-title: Hematology
  doi: 10.1080/10245330310001638974
– volume: 97
  start-page: 3473
  year: 2000
  ident: 9561_CR8
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.050585397
– volume: 48
  start-page: 1468
  year: 2007
  ident: 9561_CR27
  publication-title: Leuk Lymphoma
  doi: 10.1080/10428190701534473
– volume: 528
  start-page: 27
  year: 2005
  ident: 9561_CR35
  publication-title: Eur J Pharmacol
  doi: 10.1016/j.ejphar.2005.10.068
– volume: 93
  start-page: 496
  year: 1999
  ident: 9561_CR31
  publication-title: Blood
  doi: 10.1182/blood.V93.5.1496
– volume: 31
  start-page: 1633
  year: 2007
  ident: 9561_CR30
  publication-title: Leuk Res
  doi: 10.1016/j.leukres.2007.04.009
– volume: 11
  start-page: 293
  year: 2001
  ident: 9561_CR9
  publication-title: Pharmacogenetics
  doi: 10.1097/00008571-200106000-00003
– volume: 54
  start-page: 1295
  year: 2002
  ident: 9561_CR3
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/S0169-409X(02)00064-9
– volume: 28
  start-page: 259
  year: 2009
  ident: 9561_CR23
  publication-title: DNA Cell Biol
  doi: 10.1089/dna.2008.0826
– volume: 38
  start-page: 539
  year: 2007
  ident: 9561_CR22
  publication-title: Arch Med Res
  doi: 10.1016/j.arcmed.2007.02.005
– ident: 9561_CR21
  doi: 10.1007/s12032-010-9456-9
– volume: 81
  start-page: 39
  year: 2005
  ident: 9561_CR13
  publication-title: Int J Hematol
  doi: 10.1532/IJH97.E0418
– volume: 80
  start-page: 427
  year: 2006
  ident: 9561_CR14
  publication-title: Clin Pharmacol Ther
  doi: 10.1016/j.clpt.2006.07.005
– reference: 10500782 - Adv Exp Med Biol. 1999;457:71-5
– reference: 16331627 - Int J Cancer. 2006 May 1;118(9):2195-201
– reference: 15717687 - Int J Hematol. 2005 Jan;81(1):39-44
– reference: 16321374 - Eur J Pharmacol. 2005 Dec 28;528(1-3):27-36
– reference: 17107902 - Leuk Lymphoma. 2006 Nov;47(11):2308-13
– reference: 14749689 - Clin Pharmacol Ther. 2004 Jan;75(1):13-33
– reference: 17112800 - Clin Pharmacol Ther. 2006 Nov;80(5):427-39
– reference: 16769591 - Haematologica. 2006 Jun;91(6):848-51
– reference: 9893619 - Eur J Cancer. 1998 Sep;34(10):1493-9
– reference: 12175731 - Hum Immunol. 2002 Sep;63(9):765-70
– reference: 20204543 - Med Oncol. 2011 Mar;28(1):265-9
– reference: 19388849 - DNA Cell Biol. 2009 May;28(5):259-63
– reference: 17488488 - Br J Haematol. 2007 Jun;137(5):454-6
– reference: 10029576 - Blood. 1999 Mar 1;93(5):1496-501
– reference: 17568669 - Leuk Res. 2007 Dec;31(12):1633-40
– reference: 10477713 - Blood. 1999 Sep 15;94(6):1848-54
– reference: 7912754 - Leuk Res. 1994 Jul;18(7):475-84
– reference: 16103629 - Acta Haematol. 2005;114(2):78-83
– reference: 11980438 - Cell Mol Biol Lett. 2002;7(1):92-5
– reference: 18408561 - Pharmacogenet Genomics. 2008 May;18(5):383-9
– reference: 14631505 - Bull Exp Biol Med. 2003 Aug;136(2):183-5
– reference: 11503014 - Clin Pharmacol Ther. 2001 Aug;70(2):189-99
– reference: 12406646 - Adv Drug Deliv Rev. 2002 Nov 18;54(10):1295-310
– reference: 17560460 - Arch Med Res. 2007 Jul;38(5):539-44
– reference: 18524988 - Blood. 2008 Sep 1;112(5):2024-7
– reference: 11811787 - J Clin Immunol. 2001 Nov;21(6):420-30
– reference: 15667534 - Br J Haematol. 2005 Feb;128(3):324-32
– reference: 17701587 - Leuk Lymphoma. 2007 Aug;48(8):1556-60
– reference: 11434506 - Pharmacogenetics. 2001 Jun;11(4):293-8
– reference: 15203864 - Hematology. 2004 Apr;9(2):91-105
– reference: 15059065 - Eur J Haematol. 2004 May;72(5):314-21
– reference: 1360821 - Ann Hematol. 1992 Dec;65(6):241-6
– reference: 18639335 - Leuk Res. 2009 Feb;33(2):332-5
– reference: 19468203 - Acta Haematol. 2009;121(4):187-95
– reference: 10716719 - Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3473-8
– reference: 16507781 - Blood. 2006 Jun 15;107(12):4871-9
SSID ssj0021529
Score 2.0294774
Snippet Patients with B-chronic lymphocytic leukemia present diverse clinical features, genetic abnormalities, variable response to treatment, and heterogeneous...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1549
SubjectTerms Aged
ATP Binding Cassette Transporter, Sub-Family B
ATP-Binding Cassette, Sub-Family B, Member 1 - genetics
Biomarkers, Tumor - genetics
CD38 antigen
Cell Separation
Female
Flow Cytometry
Genes, Immunoglobulin Heavy Chain
Genetic Predisposition to Disease
Genotype
Hematology
Humans
Immunoglobulin Variable Region - genetics
Internal Medicine
Leukemia
Leukemia, Lymphocytic, Chronic, B-Cell - genetics
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Leukemia, Lymphocytic, Chronic, B-Cell - pathology
Male
Medicine
Medicine & Public Health
Neoplasm Staging
Oncology
Original Paper
Pathology
Polymerase Chain Reaction
Polymorphism, Single Nucleotide
Prognosis
SummonAdditionalLinks – databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVkJcoLyXtshIHHjIVTZ-ZMOtLX0ItBzQViqnKHZssWo3WeHksPx6xs5jBaVIvUXKxB7b45n5MuMxwBv0CQoW5T5TLTWUW2np1HJGhVCGxwZ99gAUZ1_l2Tn_fCEuunPcrs9270OSQVNvDrv5y76pD976w5g0vQtbwuOTEWwdnH7_cjzgLDRJacBZIqFo34dg5r8a-dMcXfMxr8VHg9k5eQjznuE22-Ryv6nVvv71Vy3HW45oGx50big5aOXmEdwx5WO4N-sC7U-gnn36RidkVV2tlxUuxcItHXl7GsskmZO8LMgRQw9o_o4sSnJIdVthlyDx6kel17V_Ns2lWS7yj0hO2rOYpCqJa1xIpAk5uevQlE8RKyu3cE_h_OR4fnRGuwsaqOYRq6lB7KTQ4mshuUTVh7oyL5jMFU-Esh7aGa5spFFHMM8g-p4ytpEyE2ZlMUnYMxiVVWleAGGsiA1TKo6t5aLQuW8zFaqQWtmpnI4h6tcp0131cn-JxlW2qbvsZzPD2cz8bGbpGN4Pn6za0h3_I97pFz_rdrHLUl98x7MxhtfDW9x-PqaSl6ZqnEdOHIeF2H4M5AaaFIUQ1WCEg3jeitXAT4wADSExdvChF5FN9zcy-_JW1DtwP_wIDzk4uzCqfzZmDz2pWr3qds5vOBQPxQ
  priority: 102
  providerName: Springer Nature
Title MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis
URI https://link.springer.com/article/10.1007/s12032-010-9561-9
https://www.ncbi.nlm.nih.gov/pubmed/20496015
https://www.proquest.com/docview/904516495
https://www.proquest.com/docview/1464507274
https://www.proquest.com/docview/905679308
Volume 28
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1559-131X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021529
  issn: 1357-0560
  databaseCode: AFBBN
  dateStart: 19970301
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1559-131X
  dateEnd: 20171231
  omitProxy: true
  ssIdentifier: ssj0021529
  issn: 1357-0560
  databaseCode: 7X7
  dateStart: 19970301
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1559-131X
  dateEnd: 20171231
  omitProxy: true
  ssIdentifier: ssj0021529
  issn: 1357-0560
  databaseCode: BENPR
  dateStart: 19970301
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1559-131X
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0021529
  issn: 1357-0560
  databaseCode: AGYKE
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1559-131X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0021529
  issn: 1357-0560
  databaseCode: U2A
  dateStart: 19970101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1RT9swELYYvPAyMcG2AquMxAPbZC2NHafhBRUoICbQhFqpPEWxY4sKSMqcPvTf785JU00InhIlTuycz3f35c53hByCTZDzIMNItcQwYaVlfSs4iyJlRGjAZvdA8eZWXo3F9SSaNLE5rgmrXMpEL6jzUuM_8l8JJkKRYM6fzF4YFo1C52pTQeMD2eiBpYJMHU9WeAtUU-LxVhQz0POtU9PvnMPK4Qw9wbizkyX_q6VXtuYrP6lXPxdb5GNjN9JBPdGfyJoptkl1c37HenRWPgGCB4JN3bOjR5ehjOMRzYqcnnGwU0bf6bSgp0zXeXApNJ49lHpR4bmZP5rnaXYMzWm9Y5KWBXVz58NdfOTswr8KA7mK0k3dDhlfDEdnV6wpo8C0CHjFDCAcBXpZR1JIEFAg0bKcy0yJOFIWAZgRygYaVjLHAYKFKEMbKNPjVua9mH8m60VZmK-Ecp6HhisVhtaKKNcZvjOJVC61sn3Z75BgScVUNznGsdTFU7rKjoyET4HwKRI-TTrkR_vIrE6w8V7jveXUpM1ac2nLGR1y0N6FRYKej6ww5dwhvhHwWYDAO4S-0SYBFgFhFcBHfKknvR1PCDAKgCt08HPJBavu3xzs7ruD3SOb_ve0j4zZJ-vV37n5BvZNpbqei7tkY3B5_3sIx9Ph7Z87uDoOB_8AWKn2-A
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-N8QAvCMRXGQwjgcSHLNLYcZpJ0wQbo2PrHlAn9S2LE1tUrEnBqVD_KP5H7pwmFZq2t71FiuPY5zvf73znO4DXiAkKEWQUqZYYLq2yfGCl4FGkjQwNYnZvKI5O1fBMfptEkw34296FobDKdk_0G3VR5XRG_jGhRCgK4fze_BenolHkXG0raDRccWyWf9Bic7tHB7i8b8Lw8Mt4f8hXRQV4LgNRc4N4X6OWyiMlFYoryndWCJVpGUfakjlipLZBjnyNyCZGhYrbhQ206Qurin4ssN9bcFuKQFKq_niytu9QFSbevotijriic6L6m3pUqZyT55lukvLkfzV4Cdte8st6dXd4H-6tcCr71DDWA9gw5UOoRwffeZ_Nq4vlrMIFmrqZY2-_0gTGLCsLti8QF43fsWnJPvO8ybvLsPH8R5Uva3o2i59mNs12sDlrbmiyqmRu4Xx4jY_UXfquKHCsrNzUPYKzG6HwY9gsq9I8BSZEERqhdRhaK6Miz6jPJNKFyrUdqEEPgpaKab7KaU6lNS7SdTZmInyKhE-J8GnSg_fdJ_Mmocd1jbfapUlXsu3SjhN78Kp7i0JJnpasNNXCkT0lcVpo8feAXdEmQRbBzTHASTxpFr0bT4hmGxrK-IMPLResf3_lYJ9dO9iXcGc4Hp2kJ0enx1tw1x-N-6ic57BZ_16YF4itar3tOZrB-U2L0D-D6y5u
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3raxQxEA-1gvhFFF9nfURQ8EHo3uaxt4KI9jxba4vIFe7buskmeNjbPc0ecn-a_50z2cchpf3WbwubzSaTmcz8MpMZQp6BTVDwKMdItdQy4ZRjIyc4k1JbEVuw2QNQPDpW-yfi80zOtsjf7i4MhlV2e2LYqIvK4Bn5boqJUBSY87uujYr4Op68W_5iWEAKHa1dNY2GQw7t-g-gN__2YAxL_TyOJx-ne_usLTDAjIh4zSzY_ho0lpFKKBBdkPW84CrXIpHaITSxQrvIAI-DlZOAcoWtw0XaDrlTxTDh0O8VcjXhgmM0WTLbYD1Qi2nAejJhYGP0DtVwaw-rljP0QuOtUpb-rxLP2LlnfLRB9U1ukhutzUrfN0x2i2zZ8japj8bf2JAuq9P1ooLFmvuFpy8-4QSmNC8LugfjldOXdF7SD8w0OXgpNF7-qMy6xme7-mkX8_wNNKfNbU1aldSvfAi1CVG769AVBpGVlZ_7O-TkUih8l2yXVWnvE8p5EVuudRw7J2RhcuwzlbpQRruRGg1I1FExM21-cyyzcZptMjMj4TMgfIaEz9IBedV_smySe1zUeKdbmqyVc5_1XDkgT_u3IKDodclLW608YisB0wL0PyD0nDYpsAhslBFM4l6z6P14YoBwAJrhB687Ltj8_tzBPrhwsE_INRCe7MvB8eEOuR5OyUOAzkOyXf9e2UdgZtX6cWBoSr5ftgT9A_OtMqk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MDR-1+polymorphisms+%28G2677T+and+C3435T%29+in+B-chronic+lymphocytic+leukemia%3A+an+impact+on+susceptibility+and+prognosis&rft.jtitle=Medical+oncology+%28Northwood%2C+London%2C+England%29&rft.au=Penna%2C+G&rft.au=Allegra%2C+A&rft.au=Alonci%2C+A&rft.au=Aguennouz%2C+M&rft.date=2011-12-01&rft.issn=1357-0560&rft.eissn=1559-131X&rft.volume=28&rft.issue=4&rft.spage=1549&rft.epage=1554&rft_id=info:doi/10.1007%2Fs12032-010-9561-9&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1357-0560&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1357-0560&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1357-0560&client=summon